Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population
- PMID: 27411699
- PMCID: PMC4955932
- DOI: 10.2337/dc15-2399
Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population
Abstract
Objective: Historically, mortality in type 1 diabetes has exceeded that in the general population. We compared mortality in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study cohort to that of the current general U.S.
Research design and methods: The DCCT (1983-1993) compared intensive versus conventional therapy, with HbA1c levels of ∼7 vs. 9%, respectively, over an average of 6.5 years of treatment. EDIC is the observational follow-up study of the DCCT (1994 to the present). Vital status was ascertained for 97.5% of the original DCCT cohort (n = 1,441) after a mean of 27 years follow-up. Expected mortality during DCCT/EDIC was estimated using the current age-, sex-, and race-specific risks in the general U.S. population, and the observed versus expected mortality compared using standardized mortality ratios (SMRs) and Poisson regression models.
Results: Mortality in the DCCT intensive therapy group was nonsignificantly lower than that in the general U.S. population (SMR = 0.88 [95% CI 0.67, 1.16]), whereas mortality in the DCCT conventional therapy group was significantly greater than that in the general population (SMR = 1.31 [95% CI 1.05, 1.65]). The SMR increased with increasing mean HbA1c, and above an HbA1c of 9%, the rate of increase in SMR among females was greater than that among males.
Conclusions: Overall mortality in the combined DCCT/EDIC cohort was similar to that of the general population but was higher in the DCCT conventional therapy group. Mortality increased significantly with increasing mean HbA1c, more so among females than males, especially for HbA1c >9%.
Trial registration: ClinicalTrials.gov NCT00360815 NCT00360893.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Figures
Comment in
-
Making a Difference With Diabetes Research and Care.Diabetes Care. 2016 Aug;39(8):1309-10. doi: 10.2337/dci16-0016. Diabetes Care. 2016. PMID: 27457634 No abstract available.
Similar articles
-
Realising the long-term promise of insulin therapy: the DCCT/EDIC study.Diabetologia. 2021 May;64(5):1049-1058. doi: 10.1007/s00125-021-05397-4. Epub 2021 Feb 6. Diabetologia. 2021. PMID: 33550441 Review.
-
Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study.Diabetes Care. 2017 Aug;40(8):1010-1016. doi: 10.2337/dc16-2723. Epub 2017 May 26. Diabetes Care. 2017. PMID: 28550194 Free PMC article. Clinical Trial.
-
Effects of Prior Intensive Insulin Therapy and Risk Factors on Patient-Reported Visual Function Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort.JAMA Ophthalmol. 2016 Feb;134(2):137-45. doi: 10.1001/jamaophthalmol.2015.4606. JAMA Ophthalmol. 2016. PMID: 26584339 Free PMC article. Clinical Trial.
-
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.Cochrane Database Syst Rev. 2014 Feb 14;2014(2):CD009122. doi: 10.1002/14651858.CD009122.pub2. Cochrane Database Syst Rev. 2014. PMID: 24526393 Free PMC article. Review.
-
Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.Diabetes Care. 1999 Jan;22(1):99-111. doi: 10.2337/diacare.22.1.99. Diabetes Care. 1999. PMID: 10333910 Free PMC article.
Cited by
-
Harnessing the Synergy of SGLT2 Inhibitors and Continuous Ketone Monitoring (CKM) in Managing Heart Failure among Patients with Type 1 Diabetes.Healthcare (Basel). 2024 Mar 29;12(7):753. doi: 10.3390/healthcare12070753. Healthcare (Basel). 2024. PMID: 38610175 Free PMC article. Review.
-
Exploring the Impact of Glycemic Control on Diabetic Retinopathy: Emerging Models and Prognostic Implications.J Clin Med. 2024 Jan 31;13(3):831. doi: 10.3390/jcm13030831. J Clin Med. 2024. PMID: 38337523 Free PMC article. Review.
-
Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis.Front Endocrinol (Lausanne). 2024 Jan 19;14:1285147. doi: 10.3389/fendo.2023.1285147. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38313835 Free PMC article.
-
All-cause, premature, and cardiovascular death attributable to socioeconomic and ethnic disparities among New Zealanders with type 1 diabetes 1994-2019: a multi-linked population-based cohort study.BMC Public Health. 2024 Jan 25;24(1):298. doi: 10.1186/s12889-023-17326-8. BMC Public Health. 2024. PMID: 38273238 Free PMC article.
-
Allo Beta Cell transplantation: specific features, unanswered questions, and immunological challenge.Front Immunol. 2023 Nov 23;14:1323439. doi: 10.3389/fimmu.2023.1323439. eCollection 2023. Front Immunol. 2023. PMID: 38077372 Free PMC article. Review.
References
-
- Borch-Johnsen K, Kreiner S, Deckert T. Mortality of type 1 (insulin-dependent) diabetes mellitus in Denmark: a study of relative mortality in 2930 Danish type 1 diabetic patients diagnosed from 1933 to 1972. Diabetologia 1986;29:767–772 - PubMed
-
- Skrivarhaug T, Bangstad HJ, Stene LC, Sandvik L, Hanssen KF, Joner G. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 2006;49:298–305 - PubMed
-
- Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992-1999. Diabetologia 2006;49:660–666 - PubMed
-
- Shankar A, Klein R, Klein BEK, Moss SE. Association between glycosylated hemoglobin level and cardiovascular and all-cause mortality in type 1 diabetes. Am J Epidemiol 2007;166:393–402 - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical